Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Apr, 2016 | Pages:
92 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Chagas Disease (American Trypanosomiasis) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Chagas Disease (American Trypanosomiasis) - Pipeline Review, H1 2016', provides an overview of the Chagas Disease (American Trypanosomiasis) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chagas Disease (American Trypanosomiasis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chagas Disease (American Trypanosomiasis) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Chagas Disease (American Trypanosomiasis) - The report reviews pipeline therapeutics for Chagas Disease (American Trypanosomiasis) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Chagas Disease (American Trypanosomiasis) therapeutics and enlists all their major and minor projects - The report assesses Chagas Disease (American Trypanosomiasis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Chagas Disease (American Trypanosomiasis) Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Chagas Disease (American Trypanosomiasis) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Chagas Disease (American Trypanosomiasis) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Content 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Chagas Disease (American Trypanosomiasis) Overview 10 Therapeutics Development 11 Pipeline Products for Chagas Disease (American Trypanosomiasis) - Overview 11 Pipeline Products for Chagas Disease (American Trypanosomiasis) - Comparative Analysis 12 Chagas Disease (American Trypanosomiasis) - Therapeutics under Development by Companies 13 Chagas Disease (American Trypanosomiasis) - Therapeutics under Investigation by Universities/Institutes 14 Chagas Disease (American Trypanosomiasis) - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Chagas Disease (American Trypanosomiasis) - Products under Development by Companies 18 Chagas Disease (American Trypanosomiasis) - Products under Investigation by Universities/Institutes 19 Chagas Disease (American Trypanosomiasis) - Companies Involved in Therapeutics Development 21 Anacor Pharmaceuticals, Inc. 21 Bayer AG 22 Eisai Co., Ltd. 23 GlaxoSmithKline Plc 24 Grupo Praxis Pharmaceutical SA 25 KaloBios Pharmaceuticals, Inc. 26 Merck & Co., Inc. 27 Panacela Labs, Inc. 28 Sanofi 29 SEEK Group 30 Chagas Disease (American Trypanosomiasis) - Therapeutics Assessment 31 Assessment by Monotherapy Products 31 Assessment by Target 32 Assessment by Mechanism of Action 34 Assessment by Route of Administration 36 Assessment by Molecule Type 38 Drug Profiles 40 benznidazol - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 benznidazole - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 chagas disease (bivalent) vaccine - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 chagas disease vaccine - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 chagas disease vaccine - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 chagas disease vaccine - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Chagas disease vaccine - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Cz-007 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Cz-008 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 EPLBS-1246 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 EPLBS-967 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 fexinidazole - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 fosravuconazole - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 K-777 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Monoclonal Antibody for Chagas - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 NEU-321 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 nifurtimox - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 nifurtimox SR - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 posaconazole - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 Small Molecule to Inhibit Cruzipain for Chagas Disease - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 Small Molecule to Inhibit SOD for Chagas Disease and Leishmaniasis - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 Small Molecules for Chagas Disease - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 Small Molecules for Chagas Disease - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 Small Molecules for Chagas Disease - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 Small Molecules for Chagas Disease - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 Small Molecules for Chagas Disease - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 Small Molecules for Chagas Disease - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 Small Molecules for Infectious Diseases - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 Small Molecules for Infectious Diseases - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 Small Molecules for Protozoal Infections - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 Small Molecules to Inhibit Lanosterol 14 alpha-Demethylase for Chagas Disease - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 Small Molecules to Inhibit Proline Racemase for Chagas Disease - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 VNI - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 XELRYX-3 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 Chagas Disease (American Trypanosomiasis) - Recent Pipeline Updates 80 Chagas Disease (American Trypanosomiasis) - Dormant Projects 83 Chagas Disease (American Trypanosomiasis) - Discontinued Products 84 Chagas Disease (American Trypanosomiasis) - Product Development Milestones 85 Featured News & Press Releases 85 May 07, 2015: UTMB researchers devise vaccine that provides long-term protection against Chagas disease 85 Dec 26, 2013: New Drug Candidates Show Promise for Cure for Chagas Disease 86 Nov 14, 2013: Drug Trial for Leading Parasitic Killer of the Americas Shows Mixed Results but Provides New Evidence for Improved Therapy 86 May 03, 2013: Funding boost for GSK's open innovation research into diseases affecting the developing world 88 Apr 30, 2012: NYU School of Medicine Receives Support From The Tres Cantos Open Lab Foundation To Discover New Drugs Against Chagas Disease 89 Mar 12, 2012: DNDi Receives
List of Tables
Number of Products under Development for Chagas Disease (American Trypanosomiasis), H1 2016 11 Number of Products under Development for Chagas Disease (American Trypanosomiasis) - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 13 Number of Products under Investigation by Universities/Institutes, H1 2016 14 Comparative Analysis by Late Stage Development, H1 2016 15 Comparative Analysis by Clinical Stage Development, H1 2016 16 Comparative Analysis by Early Stage Development, H1 2016 17 Products under Development by Companies, H1 2016 18 Products under Investigation by Universities/Institutes, H1 2016 19 Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 20 Chagas Disease (American Trypanosomiasis) - Pipeline by Anacor Pharmaceuticals, Inc., H1 2016 21 Chagas Disease (American Trypanosomiasis) - Pipeline by Bayer AG, H1 2016 22 Chagas Disease (American Trypanosomiasis) - Pipeline by Eisai Co., Ltd., H1 2016 23 Chagas Disease (American Trypanosomiasis) - Pipeline by GlaxoSmithKline Plc, H1 2016 24 Chagas Disease (American Trypanosomiasis) - Pipeline by Grupo Praxis Pharmaceutical SA, H1 2016 25 Chagas Disease (American Trypanosomiasis) - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2016 26 Chagas Disease (American Trypanosomiasis) - Pipeline by Merck & Co., Inc., H1 2016 27 Chagas Disease (American Trypanosomiasis) - Pipeline by Panacela Labs, Inc., H1 2016 28 Chagas Disease (American Trypanosomiasis) - Pipeline by Sanofi, H1 2016 29 Chagas Disease (American Trypanosomiasis) - Pipeline by SEEK Group, H1 2016 30 Assessment by Monotherapy Products, H1 2016 31 Number of Products by Stage and Target, H1 2016 33 Number of Products by Stage and Mechanism of Action, H1 2016 35 Number of Products by Stage and Route of Administration, H1 2016 37 Number of Products by Stage and Molecule Type, H1 2016 39 Chagas Disease (American Trypanosomiasis) Therapeutics - Recent Pipeline Updates, H1 2016 80 Chagas Disease (American Trypanosomiasis) - Dormant Projects, H1 2016 83 Chagas Disease (American Trypanosomiasis) - Discontinued Products, H1 2016 84
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
